Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry
Maher Hanoun(Essen University Hospital), Christine Hanoun(Essen University Hospital), Michael Krämer(University Hospital Carl Gustav Carus), Hermann Einsele(Universitätsklinikum Würzburg), Sebastian Scholl(Jena University Hospital), Björn Steffen(Goethe University Frankfurt), Christoph Röllig(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Carsten Müller‐Tidow(Heidelberg University), Hans Christian Reinhardt(German Cancer Research Center), Claudia D. Baldus(University Hospital Schleswig-Holstein), Andreas Hochhaus(Jena University Hospital), Dirk Niemann(Gemeinschaftsklinikum Mittelrhein), Tim H. Brümmendorf(National University Cancer Institute, Singapore), Johannes Kullmer(DIAKO), Andreas Neubauer(RWTH Aachen University), Edgar Jost(Universitätsklinikum Aachen), Mathias Hänel(Klinikum Chemnitz), Leo Ruhnke(Krankenhaus Dresden-Friedrichstadt), Lars Fransecky, Sabrina Kraus(Universitätsklinikum Würzburg), Christoph Schliemann(University Hospital Münster), Ruth Seggewiss-Bernhard(Sozialstiftung Bamberg), Ulrich Kaiser(University of Applied Sciences Landshut), Uwe Platzbecker(National Center for Tumor Diseases), Stefan W. Krause(Universitätsklinikum Erlangen), Hubert Serve(Goethe University Frankfurt), Tim Sauer(Heidelberg University), Martin Kaufmann(Robert Bosch Hospital), Martin Görner(Klinikum Bielefeld), Gerhard Held(Saarland University), Jan‐Henrik Mikesch(University Hospital Münster), Kerstin Schäfer‐Eckart(Nuremberg Hospital)
Cited by 9
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k